schliessen

Filtern

 

Bibliotheken

Current Standards of Chemotherapy for Pancreatic Cancer

Pancreatic cancer has a dismal prognosis due to the early development of systemic metastatic disease. Chemotherapeutic agents are the only systemic therapy that offers patients meaningful benefit. This study reviewed the literature for recently published Phase III clinical trials whose results have... Full description

Journal Title: Clinical therapeutics 2017-11, Vol.39 (11), p.2125-2134
Main Author: Saung, May Tun
Other Authors: Zheng, Lei
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: United States: Elsevier Inc
ID: ISSN: 0149-2918
Link: https://www.ncbi.nlm.nih.gov/pubmed/28939405
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5705388
title: Current Standards of Chemotherapy for Pancreatic Cancer
format: Article
creator:
  • Saung, May Tun
  • Zheng, Lei
subjects:
  • adjuvant
  • Adjuvant treatment
  • Analysis
  • Antineoplastic Agents - therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols - adverse effects
  • Antineoplastic Combined Chemotherapy Protocols - therapeutic use
  • Article
  • Cancer
  • capecitabine
  • Deoxycytidine - analogs & derivatives
  • Deoxycytidine - therapeutic use
  • Development and progression
  • Drug therapy, Combination
  • FOLFIRINOX
  • gemcitabine
  • Humans
  • liposomal irinotecan
  • liposomal irinotecan metastatic
  • Medical colleges
  • Medical research
  • Medicine, Experimental
  • Metastasis
  • metastatic
  • nab-paclitaxel
  • Pancreatic cancer
  • Pancreatic Neoplasms - drug therapy
ispartof: Clinical therapeutics, 2017-11, Vol.39 (11), p.2125-2134
description: Pancreatic cancer has a dismal prognosis due to the early development of systemic metastatic disease. Chemotherapeutic agents are the only systemic therapy that offers patients meaningful benefit. This study reviewed the literature for recently published Phase III clinical trials whose results have guided the current standards of chemotherapy for pancreatic cancer. Although combination chemotherapy regimens are shown to be superior to gemcitabine monotherapy for both metastatic pancreatic cancer and adjuvant chemotherapy after surgical resection, it should be recognized that all combination chemotherapy regimens offer only limited benefits. In addition, there is a paucity of clinical trials that directly compare the various combination chemotherapy regimens. With the advancement of systemic cancer treatment beyond chemotherapy, it is important to devote more investigation into better understanding the biology of these chemotherapy regimens, such that we combine them with targeted therapeutics and immunotherapeutics in a rational and scientific manner. For the current treatment of pancreatic cancer, the available chemotherapy regimens have shown modest but statistically significant improvements in survival. However, it is important to avoid cross-comparisons of trials and choose regimens based on patient characteristics and the side-effect profiles of the regimen.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0149-2918
fulltext: fulltext
issn:
  • 0149-2918
  • 1879-114X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6542683
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5705388
sourceformatXML
sourcesystemPC
galeidA523215408
sourcerecordidA523215408
originalsourceidFETCH-LOGICAL-1606t-15612b234a7feed4b14fb844adc5fd939b5d2f1a1a6c84f2b26d01b75131e2e03
addsrcrecordideNqNUkGP1CAYbYzGHVf_gvbopZWPQoGDJpPJumuyiSZq4o1Q-Nhh0paRdjbZfy-zXSeuF4UDBN57vLxHUbwBUgOB9t2utn0Y5y0mU1MCoiayJsCfFCuQQlUA7MfTYkWAqYoqkGfFi2naEUIaxenz4oxK1ShG-KoQm0NKOM7l19mMziQ3ldGXmy0O8V59f1f6mMovZrQJzRxsuclbTC-LZ970E756WM-L7x8vvm2uquvPl5826-sKWtLOFfAWaEcbZoRHdKwD5jvJmHGWe5dNdNxRDwZMayXzGdo6Ap3g0ABSJM158WHR3R-6AZ3NVpPp9T6FwaQ7HU3Qj2_GsNU38VZzQXgjZRa4WgTiHkcTEj7iuhFnHZ2mrdAOBWlbRWQeDFmDytiuFcooNN45m6XePnhJ8ecBp1kPYbLY92bEeJg0KEZFzlw0GVov0BvTow6jj9mczdPhEGwc0Yd8vua0ocAZOdoUC8GmOE0J_ckmEH2sXO_0qXJ9rFwTqXPlmfn6z4ROvN8dZ8D7v6RtmHOV8RhY6P_jgfXCx9zzbcCkJxswfwKX07SzdjH8U-MXAI3WGQ
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1942701473
display
typearticle
titleCurrent Standards of Chemotherapy for Pancreatic Cancer
sourceAlma/SFX Local Collection
creatorSaung, May Tun ; Zheng, Lei
creatorcontribSaung, May Tun ; Zheng, Lei
descriptionPancreatic cancer has a dismal prognosis due to the early development of systemic metastatic disease. Chemotherapeutic agents are the only systemic therapy that offers patients meaningful benefit. This study reviewed the literature for recently published Phase III clinical trials whose results have guided the current standards of chemotherapy for pancreatic cancer. Although combination chemotherapy regimens are shown to be superior to gemcitabine monotherapy for both metastatic pancreatic cancer and adjuvant chemotherapy after surgical resection, it should be recognized that all combination chemotherapy regimens offer only limited benefits. In addition, there is a paucity of clinical trials that directly compare the various combination chemotherapy regimens. With the advancement of systemic cancer treatment beyond chemotherapy, it is important to devote more investigation into better understanding the biology of these chemotherapy regimens, such that we combine them with targeted therapeutics and immunotherapeutics in a rational and scientific manner. For the current treatment of pancreatic cancer, the available chemotherapy regimens have shown modest but statistically significant improvements in survival. However, it is important to avoid cross-comparisons of trials and choose regimens based on patient characteristics and the side-effect profiles of the regimen.
identifier
0ISSN: 0149-2918
1EISSN: 1879-114X
2DOI: 10.1016/j.clinthera.2017.08.015
3PMID: 28939405
languageeng
publisherUnited States: Elsevier Inc
subjectadjuvant ; Adjuvant treatment ; Analysis ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Article ; Cancer ; capecitabine ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Development and progression ; Drug therapy, Combination ; FOLFIRINOX ; gemcitabine ; Humans ; liposomal irinotecan ; liposomal irinotecan metastatic ; Medical colleges ; Medical research ; Medicine, Experimental ; Metastasis ; metastatic ; nab-paclitaxel ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy
ispartofClinical therapeutics, 2017-11, Vol.39 (11), p.2125-2134
rights
02017 Elsevier HS Journals, Inc.
1Copyright © 2017 Elsevier HS Journals, Inc. All rights reserved.
2COPYRIGHT 2017 Elsevier B.V.
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1606t-15612b234a7feed4b14fb844adc5fd939b5d2f1a1a6c84f2b26d01b75131e2e03
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28939405$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Saung, May Tun
1Zheng, Lei
title
0Current Standards of Chemotherapy for Pancreatic Cancer
1Clinical therapeutics
addtitleClin Ther
descriptionPancreatic cancer has a dismal prognosis due to the early development of systemic metastatic disease. Chemotherapeutic agents are the only systemic therapy that offers patients meaningful benefit. This study reviewed the literature for recently published Phase III clinical trials whose results have guided the current standards of chemotherapy for pancreatic cancer. Although combination chemotherapy regimens are shown to be superior to gemcitabine monotherapy for both metastatic pancreatic cancer and adjuvant chemotherapy after surgical resection, it should be recognized that all combination chemotherapy regimens offer only limited benefits. In addition, there is a paucity of clinical trials that directly compare the various combination chemotherapy regimens. With the advancement of systemic cancer treatment beyond chemotherapy, it is important to devote more investigation into better understanding the biology of these chemotherapy regimens, such that we combine them with targeted therapeutics and immunotherapeutics in a rational and scientific manner. For the current treatment of pancreatic cancer, the available chemotherapy regimens have shown modest but statistically significant improvements in survival. However, it is important to avoid cross-comparisons of trials and choose regimens based on patient characteristics and the side-effect profiles of the regimen.
subject
0adjuvant
1Adjuvant treatment
2Analysis
3Antineoplastic Agents - therapeutic use
4Antineoplastic Combined Chemotherapy Protocols - adverse effects
5Antineoplastic Combined Chemotherapy Protocols - therapeutic use
6Article
7Cancer
8capecitabine
9Deoxycytidine - analogs & derivatives
10Deoxycytidine - therapeutic use
11Development and progression
12Drug therapy, Combination
13FOLFIRINOX
14gemcitabine
15Humans
16liposomal irinotecan
17liposomal irinotecan metastatic
18Medical colleges
19Medical research
20Medicine, Experimental
21Metastasis
22metastatic
23nab-paclitaxel
24Pancreatic cancer
25Pancreatic Neoplasms - drug therapy
issn
00149-2918
11879-114X
fulltexttrue
rsrctypearticle
creationdate2017
recordtypearticle
recordideNqNUkGP1CAYbYzGHVf_gvbopZWPQoGDJpPJumuyiSZq4o1Q-Nhh0paRdjbZfy-zXSeuF4UDBN57vLxHUbwBUgOB9t2utn0Y5y0mU1MCoiayJsCfFCuQQlUA7MfTYkWAqYoqkGfFi2naEUIaxenz4oxK1ShG-KoQm0NKOM7l19mMziQ3ldGXmy0O8V59f1f6mMovZrQJzRxsuclbTC-LZ970E756WM-L7x8vvm2uquvPl5826-sKWtLOFfAWaEcbZoRHdKwD5jvJmHGWe5dNdNxRDwZMayXzGdo6Ap3g0ABSJM158WHR3R-6AZ3NVpPp9T6FwaQ7HU3Qj2_GsNU38VZzQXgjZRa4WgTiHkcTEj7iuhFnHZ2mrdAOBWlbRWQeDFmDytiuFcooNN45m6XePnhJ8ecBp1kPYbLY92bEeJg0KEZFzlw0GVov0BvTow6jj9mczdPhEGwc0Yd8vua0ocAZOdoUC8GmOE0J_ckmEH2sXO_0qXJ9rFwTqXPlmfn6z4ROvN8dZ8D7v6RtmHOV8RhY6P_jgfXCx9zzbcCkJxswfwKX07SzdjH8U-MXAI3WGQ
startdate201711
enddate201711
creator
0Saung, May Tun
1Zheng, Lei
general
0Elsevier Inc
1Elsevier B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
97X8
10BOBZL
11CLFQK
125PM
sort
creationdate201711
titleCurrent Standards of Chemotherapy for Pancreatic Cancer
authorSaung, May Tun ; Zheng, Lei
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1606t-15612b234a7feed4b14fb844adc5fd939b5d2f1a1a6c84f2b26d01b75131e2e03
rsrctypearticles
prefilterarticles
languageeng
creationdate2017
topic
0adjuvant
1Adjuvant treatment
2Analysis
3Antineoplastic Agents - therapeutic use
4Antineoplastic Combined Chemotherapy Protocols - adverse effects
5Antineoplastic Combined Chemotherapy Protocols - therapeutic use
6Article
7Cancer
8capecitabine
9Deoxycytidine - analogs & derivatives
10Deoxycytidine - therapeutic use
11Development and progression
12Drug therapy, Combination
13FOLFIRINOX
14gemcitabine
15Humans
16liposomal irinotecan
17liposomal irinotecan metastatic
18Medical colleges
19Medical research
20Medicine, Experimental
21Metastasis
22metastatic
23nab-paclitaxel
24Pancreatic cancer
25Pancreatic Neoplasms - drug therapy
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Saung, May Tun
1Zheng, Lei
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8MEDLINE - Academic
9OpenAIRE (Open Access)
10OpenAIRE
11PubMed Central (Full Participant titles)
jtitleClinical therapeutics
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Saung, May Tun
1Zheng, Lei
formatjournal
genrearticle
ristypeJOUR
atitleCurrent Standards of Chemotherapy for Pancreatic Cancer
jtitleClinical therapeutics
addtitleClin Ther
date2017-11
risdate2017
volume39
issue11
spage2125
epage2134
pages2125-2134
issn0149-2918
eissn1879-114X
abstractPancreatic cancer has a dismal prognosis due to the early development of systemic metastatic disease. Chemotherapeutic agents are the only systemic therapy that offers patients meaningful benefit. This study reviewed the literature for recently published Phase III clinical trials whose results have guided the current standards of chemotherapy for pancreatic cancer. Although combination chemotherapy regimens are shown to be superior to gemcitabine monotherapy for both metastatic pancreatic cancer and adjuvant chemotherapy after surgical resection, it should be recognized that all combination chemotherapy regimens offer only limited benefits. In addition, there is a paucity of clinical trials that directly compare the various combination chemotherapy regimens. With the advancement of systemic cancer treatment beyond chemotherapy, it is important to devote more investigation into better understanding the biology of these chemotherapy regimens, such that we combine them with targeted therapeutics and immunotherapeutics in a rational and scientific manner. For the current treatment of pancreatic cancer, the available chemotherapy regimens have shown modest but statistically significant improvements in survival. However, it is important to avoid cross-comparisons of trials and choose regimens based on patient characteristics and the side-effect profiles of the regimen.
copUnited States
pubElsevier Inc
pmid28939405
doi10.1016/j.clinthera.2017.08.015
oafree_for_read